#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16940	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2255	747.8	0	.	n	.	0	C1450T	SNP	1450	1450	C	1751	1751	T	965	T,C	892,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16940	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2255	747.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1485	1485	C	1003	C,T	957,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31122	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3615	858.3	0	.	n	.	0	T695C	SNP	695	695	T	1063	1063	C	941	C	892	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31122	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3615	858.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2339	2339	C	1014	C	947	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31122	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3615	858.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2413	2413	A	964	A	912	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31122	23S	2890	2890	99.93	23S.l15.c30.ctg.1	3615	858.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	2965	2965	C	979	C,T	935,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	2118	folP	852	852	99.88	folP.l15.c4.ctg.1	1624	129.8	1	SNP	p	R228S	1	R228S	NONSYN	682	684	CGC	1095	1097	AGC	214;214;212	A;G;C,A	207;206;203,1	folP.WHO_F_01537c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5006	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3459	144.2	1	SNP	p	S91F	0	.	.	271	273	TCC	589	591	TCC	170;168;168	T;C;C	164;161;158	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5006	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3459	144.2	1	SNP	p	D95N	0	.	.	283	285	GAC	601	603	GAC	168;170;168	G;A;C	161;163;163	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5006	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3459	144.2	1	SNP	p	D95G	0	.	.	283	285	GAC	601	603	GAC	168;170;168	G;A;C	161;163;163	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1590	mtrR	633	633	97.95	mtrR.l15.c30.ctg.1	1513	105.0	0	.	p	.	0	D79N	NONSYN	235	237	GAT	665	667	AAT	197;194;195	A;A;T	188;185;183	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1590	mtrR	633	633	97.95	mtrR.l15.c30.ctg.1	1513	105.0	0	.	p	.	0	L93P	NONSYN	277	279	CTG	707	709	CCG	191;188;187	C;C;G	181;178;177	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1590	mtrR	633	633	97.95	mtrR.l15.c30.ctg.1	1513	105.0	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	743	745	CAC	191;190;190	C;A;C	180;180;180	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1590	mtrR	633	633	97.95	mtrR.l15.c30.ctg.1	1513	105.0	0	.	p	.	0	N110S	NONSYN	328	330	AAC	758	760	AGC	196;195;189	A;G;C	185;184;179	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1590	mtrR	633	633	97.95	mtrR.l15.c30.ctg.1	1513	105.0	1	SNP	p	G45D	0	.	.	133	135	GGC	563	565	GGC	207;207;204	G;G;C	200;198;195	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5388	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2961	181.3	1	SNP	p	D86N	0	.	.	256	258	GAC	546	548	GAC	232;232;236	G;A;C	220;219;224	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5388	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2961	181.3	1	SNP	p	S87I	0	.	.	259	261	AGT	549	551	AGT	238;236;239	A;G;T	226;222;226	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5388	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2961	181.3	1	SNP	p	S87W	0	.	.	259	261	AGT	549	551	AGT	238;236;239	A;G;T	226;222;226	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5388	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2961	181.3	1	SNP	p	S87R	0	.	.	259	261	AGT	549	551	AGT	238;236;239	A;G;T	226;222;226	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5388	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2961	181.3	1	SNP	p	S88P	0	.	.	262	264	TCC	552	554	TCC	241;242;240	T;C;C	231;232;230	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4428	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2548	173.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1515	1517	GGC	228;225;224	G;G;C,T	218;210;210,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4040	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2426	165.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1305	1307	GCA	230;234;233	G;C;A	215;216;215	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4040	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2426	165.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1308	1310	ATC	235;236;238	A;T;C	213;217;221	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4040	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2426	165.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1320	1322	GTG	235;234;235	G;T;G	220;213;221	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4040	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2426	165.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1320	1322	GTG	235;234;235	G;T;G	220;213;221	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4040	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2426	165.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1824	1826	ACC	221;222;220	A;C;C	202;203;204	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4040	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2426	165.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1878	1880	GCG	205;205;207	G;C;G	187;173;178	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4040	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2426	165.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1878	1880	GCG	205;205;207	G;C;G	187;173;178	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4040	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2426	165.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2001	2003	GGC	162;164;162	G;G;C	150;150;147	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4040	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2426	165.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2010	2012	GGC	155;153;155	G;G;C	138;133;138	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4040	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2426	165.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2028	2030	CCG	129;133;132	C,G;C;G	103,2;111;102	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5514	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3169	173.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2218	porA	1146	1146	99.65	porA.l15.c17.ctg.1	2055	107.6	0	.	p	.	0	S22G	NONSYN	64	66	AGC	492	494	GGC	152;152;151	G,A;G;C,A	142,1;142;142,1	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2218	porA	1146	1146	99.65	porA.l15.c17.ctg.1	2055	107.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	674	674	C	162	C	149	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3082	porB1b	1035	1035	99.03	porB1b.l15.c17.ctg.1	1366	221.2	0	.	p	.	0	E41K	NONSYN	121	123	GAA	313	315	AAA	251;252;253	A,G;A;A	238,1;241;243	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3082	porB1b	1035	1035	99.03	porB1b.l15.c17.ctg.1	1366	221.2	0	.	p	.	0	R143G	NONSYN	427	429	AGA	619	621	GGA	244;242;241	G;G;A	228;232;222	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3082	porB1b	1035	1035	99.03	porB1b.l15.c17.ctg.1	1366	221.2	0	.	p	.	0	Y211del	DEL	631	631	T	823	823	T	238	T	227	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3082	porB1b	1035	1035	99.03	porB1b.l15.c17.ctg.1	1366	221.2	0	.	p	.	0	I214V	NONSYN	640	642	ATC	829	831	GTC	232;234;237	G,A;T;C	218,1;219;226	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3082	porB1b	1035	1035	99.03	porB1b.l15.c17.ctg.1	1366	221.2	0	.	p	.	0	L218S	NONSYN	652	654	CTT	841	843	TCT	245;246;248	T;C,T;T	234;232,1;236	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3082	porB1b	1035	1035	99.03	porB1b.l15.c17.ctg.1	1366	221.2	0	.	p	.	0	S254R	NONSYN	760	762	AGT	949	951	CGT	240;235;236	C,T;G;T	227,1;226;225	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3082	porB1b	1035	1035	99.03	porB1b.l15.c17.ctg.1	1366	221.2	1	SNP	p	G120K	0	.	.	358	360	GGT	550	552	GGT	239;234;234	G;G;T,C	231;228;223,2	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3082	porB1b	1035	1035	99.03	porB1b.l15.c17.ctg.1	1366	221.2	1	SNP	p	A121N	0	.	.	361	363	GCC	553	555	GCC	232;232;229	G;C;C	225;226;225	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3082	porB1b	1035	1035	99.03	porB1b.l15.c17.ctg.1	1366	221.2	1	SNP	p	A121D	0	.	.	361	363	GCC	553	555	GCC	232;232;229	G;C;C	225;226;225	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	11588	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4807	240.2	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1986	1988	CAT	238;240;239	C,A;A;T	222,1;226;225	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1438	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	924	153.8	1	SNP	p	V57M	1	.	.	169	171	ATG	462	464	ATG	308;307;310	A;T;G	297;293;297	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
